Breakfast symposium and conference activities
to highlight capabilities of vascular robotic technology and
advancements in automation and remote treatment
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”)
(NYSE American: CVRS), a leading developer of precision vascular
robotics, announced today it will showcase the capabilities of the
CorPath® GRX system at the Transcatheter Cardiovascular
Therapeutics (TCT) 2019 Conference, to be held September 25-29 in
San Francisco, California. CorPath GRX is the only U.S. Food and
Drug Administration (“FDA”) cleared and CE-marked medical device
for robotic-assisted vascular interventions. At Corindus’ booth
1327, attendees will be able to gain hands-on experience with
CorPath GRX in an advanced simulation. In addition, the next set of
automated movements in the technIQ™ Series will be available for
demonstration.*
Corindus will also host an educational breakfast symposium
titled “Transforming Robotics into an Advanced Clinical Tool
Through Automation and Remote Capabilities” on Friday, September
27, from 6:45 to 7:45 a.m. at the Moscone Center, Room 216, Level
2, Moscone South. Corindus’ Chief Medical Officer, J. Aaron
Grantham, M.D., of St. Luke’s Hospital of Kansas City, will chair
the symposium, which will feature presentations from experts in
robotic-assisted coronary intervention. Attendees will also be able
to participate in a Q&A session with the faculty. Symposium
topics and speakers include:
• “Clinical Review” presented by Ehtisham Mahmud, M.D.
• “Robotics in Clinical Practice: Complex PCI” presented by
William Lombardi, M.D.
• “Preparing for a Remote PCI Program Today” presented by Jean
Fajadet, M.D.
• “Progress on Automation & Remote” presented by Tejas
Patel, M.D.
“My peers in the field have an appreciation for emerging
treatment modalities that advance the standard of care, and we are
excited to share the latest developments in robotic-assisted
procedures with them,” Dr. Grantham said. “As more hospitals and
health systems adopt robotic technology, it will be critical for
physicians to see CorPath GRX in action and learn the benefits of
the device for patients and practitioners through hands-on
experience.”
TCT is the world’s largest educational meeting specializing in
interventional cardiovascular medicine. For 30 years, TCT has
showcased the latest advances in current therapies and clinical
research and gathered a range of healthcare professionals with a
special interest in the field of interventional and vascular
medicine. Registration for the breakfast symposium is available at
http://www.corindus.com/tct2019.
“TCT represents the largest educational meeting in
interventional cardiovascular medicine and we are pleased that the
enthusiasm for vascular robotics continues to build,” said Mark
Toland, President and Chief Executive Officer of Corindus. “We look
forward to sharing our significant progress with remote and
automated technology with the interventional community, as we
envision these enhancing the future of patient care,” added
Toland.
To see the full list of vascular robotic events at TCT or to
sign up for demonstrations of the CorPath GRX System, please visit
http://www.corindus.com/tct2019.
To learn more about Corindus and CorPath GRX, please visit
Corindus Vascular Robotics.
*The next set of automated movements in the technIQ Series used
with CorPath GRX has not yet been cleared by the FDA; 510(k)
pending.
ABOUT CORINDUS VASCULAR ROBOTICS, INC.
Corindus Vascular Robotics, Inc. is a global technology leader
in robotic-assisted vascular interventions. The Company’s CorPath®
platform is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and vascular procedures. CorPath
GRX is the second-generation robotic-assisted technology offering
enhancements to the platform by adding important key upgrades that
increase precision, improve workflow, and extend the capabilities
and range of procedures that can be performed robotically. We are
focused on developing innovative robotic solutions to revolutionize
treatment of emergent conditions by providing specialized and
timely medical care to patients around the world. For additional
information, visit www.corindus.com, and follow @CorindusInc.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
Statements made in this release that are not statements of
historical or current facts are “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Corindus to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. Accordingly, readers should not place undue reliance on
any forward-looking statements. In addition to statements that
explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as “believes,” “belief,” “expects,”
“estimates,” “intends,” “anticipates,” “should” or “plans” to be
uncertain and forward-looking. Forward-looking statements may
include comments as to Corindus’ beliefs and expectations as to
future events and trends affecting its business and are necessarily
subject to uncertainties, many of which are outside Corindus’
control.
Examples of such statements include statements regarding or such
as:
- That Corindus will showcase the capabilities of the CorPath®
GRX system at the Transcatheter Cardiovascular Therapeutics 2019
Conference and host an educational breakfast symposium chaired by
Dr. Grantham featuring presentations from experts in robotic
assisted coronary intervention and a Q&A session for attendees
with faculty; and
- that attendees at Corindus’ booth will be able to gain hands-on
experience with the CorPath® GRX system.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are described in the sections titled “Risk Factors” in the
Company's filings with the Securities and Exchange Commission (the
“SEC”), including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as Current Reports on Form
8-K, including, but not limited to, the following: in connection
with the proposed merger between Corindus and an affiliate of
Siemens Medical Solutions USA, Inc., the risk that the required
vote of Corindus’ stockholders for the proposed merger will not be
received; the risk that one or more conditions to the proposed
merger may not be satisfied in the anticipated timeframe, or at
all, or that the proposed merger might otherwise not occur; the
risk of litigation and/or regulatory actions related to the
proposed merger; other business effects, including the effects of
industry, market, economic, political or regulatory conditions; our
ability to expand our technology platform and achieve the advances
necessary for telestenting and remote procedures, including in
humans; our ability to expand our technology platform for use in
other segments of the vascular intervention market, including
neurointerventional and other more complex cardiac interventions;
obtaining necessary regulatory approvals for the use on humans and
marketing of our products in the United States and in other
countries, including obtaining 510(k) clearance for any automated
movements in the technIQ Series or for the use of the CorPath GRX
for stroke and other neurovascular interventions; the rate of
adoption of our CorPath System and the rate of use of our
cassettes; risks associated with market acceptance, including
pricing and reimbursement; our ability to enforce our intellectual
property rights; our need for additional funds to support our
operations; our ability to manage expenses and cash flow; factors
relating to engineering, regulatory, manufacturing, sales and
customer service challenges; potential safety and regulatory issues
that could slow or suspend our sales; and the effect of credit,
financial and economic conditions on capital spending by our
potential customers. Forward-looking statements speak only as of
the date they are made. Corindus undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise that
occur after that date. More information is available on Corindus'
website at www.corindus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190918005185/en/
Media Contact: Matter for Corindus Jill Gross
978-518-4528 corindus@matternow.com www.matternow.com
Investor Contact: In-Site Communications, Inc. Lisa
Wilson 917-543-9932 ir@corindus.com
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
